Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LXRX
LEXICON PHARMACEUTICALS, INC.
NASDAQ
$2.29
▼ DOWN 1.29% (-0.03)

KEY STATISTICS

Market Cap$1.02 B
52w High$2.68
52w Low$1.03
Dividend Yield—
Frequency—
P/E-16.06
Volume2.68M
Shares Out.444.20M

COMPANY

LEADERSHIP

Michael S. Exton
CHIEF EXECUTIVE
Michael S. Exton

COMPENSATION 2026

Salary$650,576
Stock Awards$1,049,304
Incentive Plan Pay$0
All Other Comp.$15,020
Total$3,553,953

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 7, 2000
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
81

PRICE TARGET

Target High$6.00
Target Low$6.00
Target Median$6.00
Target Consensus$6.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$2.83M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2015-05-21Reverse1:7

PRICE

$2.29 ▼ DOWN 1.29% (−$0.03)
OVERLAYS
$2.27$2.28$2.30$2.319:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.29

About Lexicon Pharmaceuticals, Inc.

https://www.lexpharma.com ↗

Lexicon Pharmaceuticals, a Texas-based biopharma founded in 1995, develops oral small molecules like Sotagliflozin and LX9211, with collaborations with Bristol-Myers Squibb and Genentech.

INDUSTRY

Biotechnology

A PRODUCT LEXICON PHARMACEUTICALS, INC. IS KNOWN FOR

INPEFA (sotagliflozin)
INPEFA (sotagliflozin)

INPEFA (sotagliflozin), approved in 2023, is an oral SGLT1/2 inhibitor indicated to reduce heart failure hospitalization risk, marking Lexicon's transition to a commercial-stage biopharmaceutical company.

COMPETITORS

COMPETITOR
AZN COMPARE
JNJ COMPARE
LLY COMPARE
MRK COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$13.2M $4.26M ▼$475M ▲$475M
Product$1.01M $2.32M ▲$1.09M ▼$680K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
56
LISTED HERE
13
RANKED BY POSITION SIZE
VTI
0.00% · 7.1M
IWM
0.02% · 6.2M
XPH
0.57% · 1.4M
SCHA
0.01% · 1.1M
PRFZ
0.03% · 322.7K
XRS2.DE
0.02% · 227.7K
BBC
0.72% · 163.4K
RSSL
0.02% · 117.7K
GSSC
0.02% · 99.6K
PILL
0.38% · 40.3K
URTY
0.01% · 10.1K
TXS
0.05% · 9.3K
RESM
0.02% · 634

INSTITUTIONAL OWNERSHIP

SHARES OWNED
80.08%
HOLDERS
238
TOP 12 OF 238 · RANKED BY POSITION SIZE
Artal Group S.A.
175.2M sh · $420.37M
Fmr LLC
51.8M sh · $124.28M
Siren, L.L.C.
44.3M sh · $106.33M
Sessa Capital Im, L.P.
19.0M sh · $45.51M
Blackrock, Inc.
17.3M sh · $41.64M
Blackrock Inc.
9.9M sh · $16.62M
Vanguard Group Inc
9.6M sh · $11.05M
Point72 Asset Management, L.P.
8.3M sh · $19.8M
Geode Capital Management, LLC
6.2M sh · $14.99M
Millennium Management LLC
4.9M sh · $7.71M
State Street Corp
4.9M sh · $11.8M
Ulys, L.L.C.
4.3M sh · $25.37M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Amouyal Philippe
Sale · 89.3K shares
2026-06-03
★
DIRECTOR
DEBBANE RAYMOND
Sale · 89.3K shares
2026-06-03
★
DIRECTOR
DEBBANE RAYMOND
Purchase · 89.3K shares
2026-06-03
★
DIRECTOR
Swain Judith L
Purchase · 89.3K shares
2026-06-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
Citigroup BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
OMER$18.61COMPARE
FDMT$14.67COMPARE
OCGN$1.32COMPARE
CMPX$2.40COMPARE
FULC$3.85COMPARE
BCYC$4.20COMPARE
NMRA$1.39COMPARE
ADCT$1.14COMPARE